SUMMARY We have investigated electrolyte exchange in myasthenia gravis before and after corticotrophin therapy, using a four-isotope dilution technique. Clinical deterioration in patients on corticotrophin is associated with a fall of more than 20% in the intracellular potassium concentration, suggesting that all myasthenics so treated should be given potassium supplementation.
Myasthenia gravis is a disease of the neuromuscular junction characterised by excessive fatigue and weakness of voluntary muscles after repetitive activation, with recovery at rest. It has been suggested that acetylcholine activity at the myoneural junction is modified by immunological factors in which a thymic hormone may play some part.
Treatment with anticholinesterase drugs is frequently supplemented with corticotrophins which suppress the autoimmune activity of the thymus gland. The value of such corticotrophin therapy in myasthenia gravis is well documented but in the early days of treatment some patients deteriorate clinically and may require assisted ventilation and tracheostomy (Liversedge et al., 1974) . Sodium intake is restricted to 20 mEq per day. The risk of deterioration appeared to be lessened by dietary restriction of sodium and by potassium supplementation' but this treatment is empirical and hitherto it has not been possible to determine why some of the myasthenic patients deteriorate when treated with corticotrophins. Careful clinical assessment of the patients' muscular power and fatiguability was carried out during and after therapy and daily estimates of pulmonary vital capacity recorded using a Wright peak flow meter.
Results
Three of the eleven patients with myasthenia gravis became much worse on tetracosactrin therapy and required admission to the respiratory care unit. Their intracellular potassium concentration decreased by more than 20% from the initial pretreatment level (Table) . By contrast, the intracellular potassium concentration did not fall so Of the four control volunteers, three suffered from multiple sclerosis and the remaining patient had acute myeloid leukaemia. In none of these patients did the intracellular potassium concentration fall by more than 20 % after therapy. Earlier estimations in our laboratory have shown that the normal intracellular potassium concentration is 128 mmol/l. The estimated SD on a single determination of intracellular potassium concentration is 5.5 0.
Discussion
The simultaneous measurement of exchangeable sodium, potassium, extracellular fluid volume, and total body water not only gives information about body stores but also permits calculation of distribution of electrolytes and water between intra-and extracellular compartments and of intracellular concentration of sodium and potassium.
The determination of serum potassium concentration in neuromuscular disease is of little help to the clinician, for the values obtained have been almost uniformly within the normal range. Likewise, potassium balance studies, though suggesting gains or losses of potassium in the body over a period of time, give no indication of the total amount present in the body. Since 95 % of the potassium in the body is intracellular, neither serum values nor balance studies will reflect intracellular derangement of potassium metabolism. Exchangeable potassium and its derived value, intracellular potassium, appear to be more sensitive indicators of redistribution of body stores.
Intracellular electrode studies of the physiological properties of the neuromuscular junction in isolated intercostal muscles of normal and of myasthenic patients have shown that the resting membrane potential of single muscle fibres is 70-90 mV (Dahlback et al., 1961 
